REHOVOT, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the fourth quarter and 2016 fiscal year ended December 31, 2016, and has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission (the SEC).
“We are pleased to have achieved multiple value creating clinical and corporate milestones in the past 12 months and are making further progress toward our goal of making important new therapies available to patients with Parkinson’s disease,” said Oded Lieberman, PhD, CEO of NeuroDerm. “With positive results in our phase 2 efficacy trial of ND0612 in patients with advanced Parkinson’s disease and productive meetings with U.S. and EU regulatory authorities, we believe that we are well positioned to execute our development programs for ND0612 lead product candidates, and further advance ND0701, our apomorphine liquid formulation, in 2017. We remain on track to submit regulatory applications for ND0612 in the U.S. and EU in 2018, and look forward to initiating our follow-on PK study for ND0701 in the second half of this year.”
“We are pleased to have achieved multiple value creating clinical and corporate milestones in the past 12 months and are making further progress toward our goal of making important new therapies available to patients with Parkinson’s disease,” said Oded Lieberman, PhD, CEO of NeuroDerm. “With positive results in our phase 2 efficacy trial of ND0612 in patients with advanced Parkinson’s disease and productive meetings with U.S. and EU regulatory authorities, we believe that we are well positioned to execute our development programs for ND0612 lead product candidates, and further advance ND0701, our apomorphine liquid formulation, in 2017. We remain on track to submit regulatory applications for ND0612 in the U.S. and EU in 2018, and look forward to initiating our follow-on PK study for ND0701 in the second half of this year.”
